nivolumab
nivolumab (at a dose of 240 mg every 2 weeks for 16 weeks, followed by nivolumab at a dose of 480 mg every 4 weeks)
placebo
Dose modifications were notpermitted, but nivolumab or placebo could be interruptedor delayed
mEC - (neo)adjuvant (NA)
The patients completedneoadjuvant chemoradiotherapy, followedby complete resection,
double-blind
170 sites in 29 countries
P3/ two sided with one interim analysis. The boundaryfor statistical significance based on 396 eventsof disease recurrence or death observed at thisinterim analysis required the P value to be lessthan 0.036.
Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo.